MedTrace Logo

A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions

NCT03136237 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2017-10-26

No results posted yet for this study

Summary

This is an open-label, three part study to evaluate the effect of BCX7353 on drug transporters as well as the effect of an inhibitor of drug transport on BCX7353.

Conditions

Interventions

DRUG

BCX7353

Day 11-18 for Cohort 1, Day 7-14 for Cohort 2, Day 1 for Cohort 3

DRUG

Digoxin

Day 1 of Cohort 1

DRUG

BCX7353 + digoxin

Day 19 of Cohort 1

DRUG

Rosuvastatin

Day 1 of Cohort 2

DRUG

rosuvastatin + BCX7353

Day 15 of Cohort 1

DRUG

Cyclosporine + BCX7353

Day 14 of Cohort 3

Sponsors & Collaborators

  • BioCryst Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Firas Almazedi, MBChB, Msc, CPI · Covance Clinical

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-17
Primary Completion
2017-08-15
Completion
2017-08-15

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03136237 on ClinicalTrials.gov